Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | DARE: dara for R/R myeloma with renal impairment

Efstathios Kastritis • 16 Jun 2020
EHA 2020
Multiple Myeloma Antibodies Daratumumab Dexamethasone
DARE

Efstathios Kastritis, MD, of the University of Athens School of Medicine, Athens, Greece, discusses the efficacy and safety of daratumumab (dara) with dexamethasone in patients with relapsed/refractory (R/R) multiple myeloma and severe renal impairment as evaluated in the DARE study (NCT03450057). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Efstathios Kastritis

Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
Monitoring, diagnosing & managing cardiotoxicity in AL amyloidosis 0:52
Monitoring, diagnosing & managing cardiotoxicity in AL amyloidosis
Efstathios Kastritis • 29 May 2024
The outcomes of patients with AL amyloidosis and end-stage renal disease 1:44
The outcomes of patients with AL amyloidosis and end-stage renal disease
Efstathios Kastritis • 29 Jun 2024
Differentiating between amyloidosis and myeloma 1:22
Differentiating between amyloidosis and myeloma
Efstathios Kastritis • 29 May 2024

Related Videos

Initial results from MajesTEC-3: Tec-Dara versus DPd/DVd in patients with R/R multiple myeloma 3:53
Initial results from MajesTEC-3: Tec-Dara versus DPd/DVd in patients with R/R multiple myeloma
Luciano Costa • 16 Dec 2025
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals